AKBA · XBRL financial data

Akebia Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AKBA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	42	56*	33	44	37	46*	57	62	59	58*	54	49
Cost of revenue	18	19*	12	17	14	20*	8	10	9	13*	12	10
Research and development	13	10*	10	8	8	12*	10	11	15	27*	15	14
Selling, general and administrative	23	25*	25	27	27	28*	26	27	29	26*	30	28
Total operating expenses	37	36*	36	35	36	40*	36	38	45	54*	46	45
Operating income (loss)	(13)	1*	(15)	(9)	(13)	(14)*	14	14	4	(9)*	(5)	(6)
Other income (expense)	(0)	1*	0	(0)	(0)	0*	0	(0)	(0)	(0)*	0	(0)
Income tax expense (benefit)	—	year only	—	—	0	0*	0	0	1	1*	0	0
Net income (loss)	(14)	1*	(18)	(9)	(20)	(23)*	6	0	1	(12)*	(9)	(9)
Earnings per share, basic USD per share	(0.08)	0.00*	(0.09)	(0.04)	(0.10)	(0.10)*	0.03	0.00	0.00	(0.05)*	(0.03)	(0.03)
Earnings per share, diluted USD per share	(0.08)	0.00*	(0.09)	(0.04)	(0.10)	(0.10)*	0.03	0.00	0.00	(0.05)*	(0.03)	(0.03)
Weighted average shares, basic millions of shares	188	190*	205	210	210	219*	235	263	265	265*	267	270
Weighted average shares, diluted millions of shares	188	190*	205	210	210	219*	242	271	274	241*	267	270

Fiscal quarters (AKBA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	47	43	42	39	34	52	113	137	166	185	163	156
Accounts receivable	23	39	27	30	32	34	62	73	66	47	63	54
Inventory	18	16	26	24	20	16	20	17	19	16	13	13
Prepaid and other current assets	22	20	19	19	13	11	9	8	7	5	5	7
Total current assets	110	118	113	112	100	114	204	235	258	253	243	230
Property and equipment, net	4	4	3	3	3	2	2	2	1	1	1	2
Right-of-use asset	13	12	11	10	9	8	7	6	5	4	2	6
Goodwill	59	59	59	59	59	59	59	59	59	59	59	59
Total assets	235	242	225	220	207	221	310	346	364	377	363	350
Accounts payable	9	15	12	10	13	15	13	12	10	21	8	9
Accrued liabilities	63	68	54	54	52	63	71	92	106	122	125	110
Current portion of long-term debt	8	18	0	0	0	0	—	—	—	0	12	25
Total current liabilities	80	100	66	107	66	81	91	119	133	163	174	161
Long-term debt	35	17	30	38	38	39	47	47	48	48	36	25
Lease liability, non-current	10	9	8	6	5	4	2	1	0	0	—	4
Total liabilities	274	272	253	254	258	270	286	316	323	344	335	325
Accumulated deficit	(1,610)	(1,609)	(1,627)	(1,636)	(1,656)	(1,678)	(1,672)	(1,672)	(1,671)	(1,684)	(1,693)	(1,702)
Total stockholders' equity	(39)	(31)	(27)	(34)	(50)	(49)	25	29	42	33	27	25
Total liabilities and equity	235	242	225	220	207	221	310	346	364	377	363	350
Common shares outstanding (cover page) millions of shares	188	209	210	210	218	236	263	265	265	268	268	277

Fiscal quarters (AKBA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(14)	1*	(18)	(9)	(20)	(23)*	6	0	1	(12)*	(9)	(9)
Stock-based compensation	2*	2*	2	2*	2*	2*	2	3*	3*	3*	4	3*
Net cash from operating activities	(7)*	(2)*	(19)	(10)*	(7)*	(4)*	(14)	22*	28*	31*	(21)	4*
Purchases of property and equipment	0*	0*	0	0*	0*	0*	0	0*	0*	0*	0	1*
Net cash from investing activities	0*	0*	0	(0)*	(0)*	(0)*	0	(0)*	(0)*	(8)*	(0)	(4)*
Net cash from financing activities	0*	(1)*	18	8*	1*	22*	75	2*	1*	(5)*	(1)	(7)*
Net change in cash	(7)*	(4)*	(1)	(2)*	(5)*	18*	62	24*	29*	18*	(22)	(7)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Akebia Therapeutics	156	49	3.5*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Viridian Therapeutics	165	not reported	(105)*	113.3M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Collegium Pharmaceutical	129	200	71*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026
Neogen	172	223	13	218.3M	—	Q1 FY27 10-QAug 31, 2026
CorMedix	257	102	86*	77.9M	—	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Harrow	84	71	(9.8)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Novavax	191	57	(73)*	164.9M	9.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.